Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Targeting heterotopic ossification by inhibiting activin receptor‑like kinase 2 function (Review).

Shi F, Gao J, Zou J, Ying Y, Lin H.

Mol Med Rep. 2019 Oct;20(4):2979-2989. doi: 10.3892/mmr.2019.10556. Epub 2019 Aug 6.

2.

The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.

Lin H, Shi F, Gao J, Hua P.

Biosci Rep. 2019 Aug 2;39(8). pii: BSR20190377. doi: 10.1042/BSR20190377. Print 2019 Aug 30. Review.

3.

Hypoxia-selective allosteric destabilization of activin receptor-like kinases: A potential therapeutic avenue for prophylaxis of heterotopic ossification.

Lu G, Tandang-Silvas MR, Dawson AC, Dawson TJ, Groppe JC.

Bone. 2018 Jul;112:71-89. doi: 10.1016/j.bone.2018.03.027. Epub 2018 Apr 5.

PMID:
29626545
4.

Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial.

Pacifici M.

Bone. 2018 Apr;109:267-275. doi: 10.1016/j.bone.2017.08.010. Epub 2017 Aug 19. Review.

PMID:
28826842
5.

Heterotopic Ossification Following Upper Extremity Injury.

Agarwal S, Loder S, Levi B.

Hand Clin. 2017 May;33(2):363-373. doi: 10.1016/j.hcl.2016.12.013. Review.

6.

Postoperative nonsteroidal antiinflammatory drugs and the prevention of heterotopic ossification after cervical arthroplasty: analysis using CT and a minimum 2-year follow-up.

Tu TH, Wu JC, Huang WC, Chang HK, Ko CC, Fay LY, Wu CL, Cheng H.

J Neurosurg Spine. 2015 May;22(5):447-53. doi: 10.3171/2014.10.SPINE14333. Epub 2015 Feb 27.

PMID:
25723121
7.

Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.

Yano M, Kawao N, Okumoto K, Tamura Y, Okada K, Kaji H.

J Biol Chem. 2014 Jun 13;289(24):16966-77. doi: 10.1074/jbc.M113.526038. Epub 2014 May 5.

8.

Challenges of heterotopic ossification-Molecular background and current treatment strategies.

Łęgosz P, Drela K, Pulik Ł, Sarzyńska S, Małdyk P.

Clin Exp Pharmacol Physiol. 2018 Dec;45(12):1229-1235. doi: 10.1111/1440-1681.13025. Epub 2018 Oct 4. Review.

PMID:
30144316
9.

Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.

Culbert AL, Chakkalakal SA, Theosmy EG, Brennan TA, Kaplan FS, Shore EM.

Stem Cells. 2014 May;32(5):1289-300. doi: 10.1002/stem.1633.

10.

Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic Ossification.

Agarwal S, Loder SJ, Breuler C, Li J, Cholok D, Brownley C, Peterson J, Hsieh HH, Drake J, Ranganathan K, Niknafs YS, Xiao W, Li S, Kumar R, Tompkins R, Longaker MT, Davis TA, Yu PB, Mishina Y, Levi B.

Mol Ther. 2017 Aug 2;25(8):1974-1987. doi: 10.1016/j.ymthe.2017.01.008. Epub 2017 Jul 15.

11.

BMP and mTOR signaling in heterotopic ossification: Does their crosstalk provide therapeutic opportunities?

Wu J, Ren B, Shi F, Hua P, Lin H.

J Cell Biochem. 2019 Aug;120(8):12108-12122. doi: 10.1002/jcb.28710. Epub 2019 Apr 15.

PMID:
30989716
12.

Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.

Kawao N, Yano M, Tamura Y, Okumoto K, Okada K, Kaji H.

J Bone Miner Metab. 2016 Sep;34(5):517-25. doi: 10.1007/s00774-015-0701-3. Epub 2015 Jul 24.

PMID:
26204847
13.

Prevention and treatment of heterotopic ossification after spinal cord injury.

Banovac K, Sherman AL, Estores IM, Banovac F.

J Spinal Cord Med. 2004;27(4):376-82. Review.

PMID:
15484668
14.

Surgical Excision of Heterotopic Ossification Leads to Re-Emergence of Mesenchymal Stem Cell Populations Responsible for Recurrence.

Agarwal S, Loder S, Cholok D, Li J, Breuler C, Drake J, Brownley C, Peterson J, Li S, Levi B.

Stem Cells Transl Med. 2017 Mar;6(3):799-806. doi: 10.5966/sctm.2015-0365. Epub 2016 Oct 5.

15.

Heterotopic ossification.

Shehab D, Elgazzar AH, Collier BD.

J Nucl Med. 2002 Mar;43(3):346-53. Review.

16.

Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.

Whyte MP, Wenkert D, Demertzis JL, DiCarlo EF, Westenberg E, Mumm S.

J Bone Miner Res. 2012 Mar;27(3):729-37. doi: 10.1002/jbmr.1473.

17.

Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification.

Agarwal S, Loder S, Brownley C, Cholok D, Mangiavini L, Li J, Breuler C, Sung HH, Li S, Ranganathan K, Peterson J, Tompkins R, Herndon D, Xiao W, Jumlongras D, Olsen BR, Davis TA, Mishina Y, Schipani E, Levi B.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):E338-47. doi: 10.1073/pnas.1515397113. Epub 2015 Dec 31.

18.

Inhibition of phosphatidylinositol 3-kinase α (PI3Kα) prevents heterotopic ossification.

Valer JA, Sánchez-de-Diego C, Gámez B, Mishina Y, Rosa JL, Ventura F.

EMBO Mol Med. 2019 Sep;11(9):e10567. doi: 10.15252/emmm.201910567. Epub 2019 Aug 2.

19.

Optimal strategies for the prevention of heterotopic ossification after total hip arthroplasty: A network meta-analysis.

Cai L, Wang Z, Luo X, She W, Zhang H.

Int J Surg. 2019 Feb;62:74-85. doi: 10.1016/j.ijsu.2018.12.011. Epub 2019 Jan 4.

PMID:
30615954
20.

The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.

Upadhyay J, Xie L, Huang L, Das N, Stewart RC, Lyon MC, Palmer K, Rajamani S, Graul C, Lobo M, Wellman TJ, Soares EJ, Silva MD, Hesterman J, Wang L, Wen X, Qian X, Nannuru K, Idone V, Murphy AJ, Economides AN, Hatsell SJ.

J Bone Miner Res. 2017 Dec;32(12):2489-2499. doi: 10.1002/jbmr.3235. Epub 2017 Sep 22.

Supplemental Content

Support Center